DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?

TEVA PHARM has two hundred and seventy-six approved drugs.

There are thirty US patents protecting TEVA PHARM drugs. There are thirty-four tentative approvals on TEVA PHARM drugs.

There are four hundred and twenty-six patent family members on TEVA PHARM drugs in thirty-nine countries and four hundred and forty-five supplementary protection certificates in thirteen countries.

Summary for Teva Pharm

International Patents:	426
US Patents:	30
Tradenames:	230
Ingredients:	223
NDAs:	276
Patent Litigation for Teva Pharm:	See patent lawsuits for Teva Pharm
PTAB Cases with Teva Pharm as petitioner:	See PTAB cases with Teva Pharm as petitioner

Drugs and US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	ATOMOXETINE HYDROCHLORIDE	atomoxetine hydrochloride	CAPSULE;ORAL	079022-002	May 30, 2017	AB	RX	No	No
Teva Pharms Usa	CISPLATIN	cisplatin	INJECTABLE;INJECTION	074814-001	May 16, 2000		DISCN	No	No
Teva Pharms	OLANZAPINE AND FLUOXETINE HYDROCHLORIDE	fluoxetine hydrochloride; olanzapine	CAPSULE;ORAL	077528-003	Jun 19, 2012	AB	RX	No	No
Teva Pharms Usa	ROSIGLITAZONE MALEATE AND GLIMEPIRIDE	glimepiride; rosiglitazone maleate	TABLET;ORAL	078709-002	Apr 1, 2016		RX	No	No

Expired US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,620,847
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,939,539
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	8,367,605
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017	6,446,627

Paragraph IV (Patent) Challenges for TEVA PHARM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Delayed-release Tablets	20 mg		2015-06-03

Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

Non-Orange Book US Patents for Teva Pharm

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
6,613,900	Cephalotaxane derivatives and process for their preparation
9,345,664	Process for preparing a medicament
6,655,381	Pre-metered dose magazine for breath-actuated dry powder inhaler
9,533,111	Dose counters for inhalers, inhalers and methods of assembly thereof

International Patents for Teva Pharm Drugs

Country	Document Number	Estimated Expiration
Canada	2540580
Spain	2544437
Japan	2015231585
Japan	4897570

Supplementary Protection Certificates for Teva Pharm Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2016 00064	Denmark		PRODUCT NAME: RILPIVIRINHYDROCHLORID, EMTRICITABIN OG TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623
2016000104	Germany		PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; NAT. REG.NO/DATE: EU/1/08/455/001-014, EU/1/08/456/001-014, EU/1/08/457/001-014 20080716; FIRST REG.:CH 58450 01-03 20080408
70015	Netherlands		PRODUCT NAME: OLANZAPINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT; REGISTRATION NO/DATE: EU/1/96/022/001 - EU/1/96/022/010 19960927

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm